Pradaxa

Showing 8 posts of 53 posts found.

Pradaxa, Xarelto and apixaban vie for attention

September 6, 2010
Research and Development, Sales and Marketing Pradaxa, Xarelto, apixaban, atrial fibrilation

New data has intensified the competition between three rival would-be cardiology blockbusters. Boehringer Ingelheim’s Pradaxa (dabigatran) and Bayer’s Xarelto (rivaroxaban) …

Novel anticoagulants set to lead atrial fibrillation market

July 9, 2010
Sales and Marketing Brinavess, Multaq, Pradaxa, Xarelto, apixaban, atrial fibrilation

Novel anticoagulants set to capture the atrial fibrillation market by 2019, according to a new report. Analysts Decision Resources say …

New anti-clotting drugs: stopping the silent killers

June 28, 2010
Research and Development, Sales and Marketing Pradaxa, VTE, Xarelto, atrial fibrilation, thrombosis

Blood clots are a major killer, but the threat they pose is poorly understood by the general public compared to …

Ogilvy wins Pradaxa account

June 3, 2010
Medical Communications Boehringer, Ogilvy, Pradaxa

Boehringer Ingelheim has awarded OgilvyHealthPR the global communications brief for its oral blood-thinner Pradaxa. The agency was appointed after a …

Patients ignorant of blood clot risks

April 14, 2010
Sales and Marketing Pradaxa, VTE, thrombosis

Many patients are not aware that they are at risk from blood clots when staying in hospital, according to new …

Study boost for atrial fibrillation drugs

March 17, 2010
Research and Development Pradaxa, VTE, Xarelto, apixaban, betrixaban

Two rival drugs have both shown benefits over warfarin in patients with atrial fibrillation, according to new research. Boehringer Ingelheim’s …

Pradaxa data boosts Boehringer

September 1, 2009
Research and Development, Sales and Marketing Boehringer, Pradaxa

Boehringer Ingelheim has unveiled new positive data for its blood-thinner Pradaxa, showing it reduces the risk of stroke compared to …

Pradaxa approved by NICE

September 26, 2008
Sales and Marketing NICE, Pradaxa, clot, cv

NICE has recommended Boehringer Ingelheim's novel anti-clotting pill Pradaxa, giving it a marketing edge over Bayer's rival treatment Xarelto. Pradaxa …

Latest content